SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (80 reviews)

For research use only.

Catalog No.S1077

80 publications

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 80 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )
J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )
Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )
Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	M3fKT2Z2dmO2aX;uJGF{e2G7	NUDxfpl[OjVizszN	MU[zNEBucW5?	Mk\USG1UV8Li	MYDheJRmdnWjdHXzJJRp\SCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25ib3[gbGJFNTJiaX6gdoV{eG:wc3n2[UB1dyCGQR?=	NWTK[5JVOjZ{MkOyOVE>
MDA-MB-231	M3fHc2Z2dmO2aX;uJGF{e2G7	Mo\MNkDPxE1?	M{LmeVI1KGh?		MVjs[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>?	MmPGNlYyODB6NEi=
rBMSCs	Mnf1SpVv[3Srb36gRZN{[Xl?	NV75[2FYOTBizszN	MVuyMlUhcA>?		MV7k[ZBz\XO\|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB\|OB?=	NIG2R4UzPjB3M{K2Oi=>
MG63	M{TVRmZ2dmO2aX;uJGF{e2G7	MXWxNE8zOC9\|MDFOwG0>	MUOyOEBp		MWPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy	NWrXUIVCOjV7OUizNVI>
MG63	MV3BdI9xfG:\|aYOgRZN{[Xl?	NW[2d3BnOTBxMkCvN\|Ah\|ryP	Mn6yNlQhcA>?		NHr0S5F{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{	MV[yOVk6QDNzMh?=
HTSMCs	NXfBPYZYTnWwY4Tpc44hSXO\|YYm=	M{PDeFAvOS9zL{GwJO69VQ>?	M2XsNFEhcA>?		NXXRN25CcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	MUSyOVkzOTR4NB?=
MIA PaCa-2	Ml\iSpVv[3Srb36gRZN{[Xl?	MVWyNOKh\|ryP	MW[yOEBp		NVzkPZM6emWmdXPl[EBt[WO2YYTlJIFk[3WvdXzheIlwdiCrbjDjc41jcW6jdHnvckB4cXSqIHLveIghOi2GRzDhcoQhTC2jbHzvd4XDqA>?	NVT2fYNFOjV6OEi0PFk>
MIA PaCa-2	Mlf2SpVv[3Srb36gRZN{[Xl?	NWnxN24yOjEEoN88US=>	M3;LUVI1KGh?		NWmxUmY2emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	M{DUblI2QDh6NEi5
BxPC-3	M4LON2Z2dmO2aX;uJGF{e2G7	MmTUNlDDqM7:TR?=	NXXWNY0{OjRiaB?=		M{fZUZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	NYjq[YU3OjV6OEi0PFk>
AsPC-1	NVrqSlBXTnWwY4Tpc44hSXO\|YYm=	MWKyNOKh\|ryP	NGLBPGUzPCCq		MUDy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	NFmycnozPTh6OES4PS=>
MIA PaCa-2	MVfGeY5kfGmxbjDBd5NigQ>?	MlPYNlDDqM7:TR?=	Mo\qNlQhcA>?		Mm[0[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDD3bIVvKGOxbXLpcoVlKHerdHig[4x2[2:\|ZTDhcoFtd2e\|	MVSyOVg5QDR6OR?=
MIA PaCa-2	NGXvTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmyNOKh\|ryP	NVnuXVFrOiCq		MVLz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	MkXoNlU5QDh2OEm=
BxPC-3	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVu2[oV[OjEEoN88US=>	NFPsR\|czKGh?		MVnz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	M4PHVVI2QDh6NEi5
AsPC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PXdFIxyqEQvF2=	NXXWZXBiOiCq		Mn[yd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	M2fMdVI2QDh6NEi5
HEY	NXKzPZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOyNOKh\|ryP	MX6yJIg>		M4X0VpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	MlPyNlU5QDh2OEm=
OVCAR-3	NF:4TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\4RYt[OjEEoN88US=>	NXTQWHZnOiCq		NGe2ZZh{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MVGyOVg5QDR6OR?=
SK-OV-3	NUXWflNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzRfpMzOMLizszN	NUXpcYY5OiCq		MYrz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	NIe5W\|AzPTh6OES4PS=>
MH7A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXiyOEBp		M{Dp[ZJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5?	MmnRNlU5PjJ7Nk[=
MH7A	MXnBdI9xfG:\|aYOgRZN{[Xl?	NYLscnJsOjVizszN	MkntNlQhcA>?		NE[0Nm9z\X[ncoPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdmS3Y3XkJIJ6KFiDTjDhcoQh[2G3c3XkJIFxd3C2b4Ppd{Bw\iClZXzsd{B3cWFiYXP0bZZifGmxbjDv[kBLVkt?	MkfoNlU5PjJ7Nk[=
SCC25	NUHnb2x6TnWwY4Tpc44hSXO\|YYm=	MUiyNEDPxE1?	NWn1Zmp6OjRiaB?=		M{XTcolv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy=	MYGyOVg{PDRyMB?=
HaCaT	NFO3N2pHfW6ldHnvckBCe3OjeR?=	Mk\hOUDDvU1?	NF7NNFczPCCq		NXP1U25CcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	NXrXZmMxOjV6M{SzOVM>
HaCaT	M2\JdWZ2dmO2aX;uJGF{e2G7	MV[1JOK2VQ>?	NHLVOo0zPCCq		NWC4VHg3cW6qaXLpeJMhUU[QLd8xMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	M1LXSFI2QDN2M{Wz
HPAEpiCs	NHS2UFFHfW6ldHnvckBCe3OjeR?=	MWSxM\|MwOTBizszN	M2LBXVEhcA>?		MY\y[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	MlPMNlU4OzR7MEC=
HPAEpiCs	NWLFW5AyTnWwY4Tpc44hSXO\|YYm=	NGnNW2kyNzNxMUCg{txO	M1Pmd\|EhcA>?		M{HtRYlvcGmkaYTzJHMyWC2\|dHnteYxifGWmIFHreEBxcG:\|cHjvdplt[XSrb36gJOKh	MWSyOVc{PDlyMB?=
HPAEpiCs	NH;qfZhHfW6ldHnvckBCe3OjeR?=	MoS1NU8{NzFyIN88US=>	MWCxJIg>		M3eyS4lvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u	MlHXNlU4OzR7MEC=
K562	MXHGeY5kfGmxbjDBd5NigQ>?	NIPTO40yOMLizszN	MX:xxsBp	NVfU[oI6TE2VTx?=	M2jud4lvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	NX[3SnNMOjV4OESwOFM>
PANC-1	NFHsW45HfW6ldHnvckBCe3OjeR?=	NXzSfW5TOTBizszN	M2fCOVEhcA>?		MVjlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	MnS2NlU3OzJ{MkK=
BxPC-3	MoXySpVv[3Srb36gRZN{[Xl?	NWP1WI01OTBizszN	M3PvOVEhcA>?		NYS3V3Bm\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC=	NELTO\|YzPTZ\|MkKyNi=>
K562	NWfiPVZ3TnWwY4Tpc44hSXO\|YYm=	M2DTflAvOjVvMTFOwG0>	MlvmNlQhcA>?		MmLRd5VxeHKnc4Pld{Bz\XO4ZYLheJJwdC2rbnT1Z4VlKEh{QWigdIhwe3Cqb4L5cIF1cW:w	NEfhZWgzPTZzOUO5Ni=>
THP-1	MXvGeY5kfGmxbjDBd5NigQ>?	NVfXWmZsPSEEtV2=	NHHadnozKGh?		NHfsPYJ{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgd4VkemW2aX;uJI9nKEmOLUJOtUBqdmS3Y3XkJIJ6KDJ5T1jDbI9tKHCudYOgSnNNNTIEoB?=	MmL5NlU2QTh4NkG=
WB	MmHFSpVv[3Srb36gRZN{[Xl?	MmHTNlDjiIoQvF5CpC=>	NWSyZZZyOzEkgJntbY4>		M37GXoRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu\|rIEoIDyc4R2[3Srb36=	NIfXUFEzPTV\|ME[4Ni=>
RAW 264.7	MUfGeY5kfGmxbjDBd5NigQ>?	M1vFcVExyqEQvF2=	NWTPSJl1OzEkgJntbY4>		NFfYVY1qdmS3Y3XzJINp[XKjY4Tldol{fGmlII\hZ5VwdGG2aX;uJI9nKE:Fc9Mg	M3rZS\|I2PDZzM{m5
RAW 264.7	NYHqRW5yTnWwY4Tpc44hSXO\|YYm=	M1zwVlExyqEQvF2=	MkHCN\|DjiImvaX6=		M4LFXYF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=>	NXPrVVNCOjV2NkGzPVk>
HaCaT	MVjGeY5kfGmxbjDBd5NigQ>?	NWPDV3k2PDEEoN88US=>	NX;jNXBkOy1{NDDo	NHHVepZFVVOR	MV\y[YR2[2W\|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>?	NIixToEzPTR\|NUS4OS=>
H9c2	NFnTem5HfW6ldHnvckBCe3OjeR?=	MnjyOVDDqM7:TdMg	NF3z[oEyOiCq		NYSxbIY{emWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O=	M365e\|I2OjR3OEG4
HSCs	NV31[XE5SXCxcITvd4l{KEG\|c3H5	NXTEUYpjOjVizszN	MUeyOOKhcA>?		MVHzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	NVv2U4pxOjR7NkG5OVA>
THP-1	NHf0[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYnqU25vPzJiaB?=	MnHpSG1UVw>?	MVrJR\|UxRTRwN988US=>	MmPyNlQ5OTVyOEe=
MDDCs	NGnNWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX23NkBp	MmrmSG1UVw>?	MlzMTWM2ODJwN988US=>	MkWwNlQ5OTVyOEe=
MDDCs	NX:4c4xOTnWwY4Tpc44hSXO\|YYm=	NGXHRpIxNTF3IN88US=>	NXj6VFdQPDhiaB?=	NGexWXpFVVOR	MVrzeZBxemW\|c3XzJGlHVi4QsTDhcoQhUVBvMUCgdJJw\HWldHnvcuKh	MWCyOFgyPTB6Nx?=
MDDCs	MlXhSpVv[3Srb36gRZN{[Xl?	MofvNE0yPSEQvF2=	MYq0PEBp	NH\zU21FVVOR	NUHTdZJ5cW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v	M2fpXVI1QDF3MEi3
MDDCs	MVHGeY5kfGmxbjDBd5NigQ>?	M3XGWVExKM7:TR?=	MnPhN{42KGh?	M1[xe2ROW09?	MULicI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO\|	NITTNZgzPDhzNUC4Oy=>
macrophages	NHnhfFZHfW6ldHnvckBCe3OjeR?=	Mm\UNgKBkc7:TR?=	M4\BbFQvPeLCiXi=		MnS5Z49ueGyndHXsfUBqdmirYnn0d{BOXC2LSVmtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKE6ILd86Ri=>	MVmyOFgxQDZ\|Mx?=
PDL	NF7QbW9HfW6ldHnvckBCe3OjeR?=	NYLZW2ltOjEEoN88UeKh	NEDuc5g{OCCvaX6=	MnzBSG1UVw>?	MWjzbYdvcW[rY3HueIx6KGmwaHnibZR{KHSqZTD0[Y5{cWynIH\vdoNmNW2nZHnheIVlKEKPUD2yJIV5eHKnc4Ppc44>	NVjG[2hoOjR3NkGwPFE>
AGS	NYn4NW1DTnWwY4Tpc44hSXO\|YYm=	M3f1Z\|Uh\|ryP	NXjhNVVUOzBibXnu		NFPMTox{fXCycnXzd4V{yqBzLXnu[JVk\WRiY3HzdIF{\S16IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>?	NGrKT2kzPDV2N{i3PC=>
H520	MXnGeY5kfGmxbjDBd5NigQ>?	M1nlV\|ExyqEEtV2=	NYTvTnFyOSCq	NWXtbZdGTE2VTx?=	MUjk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	M37hOVI1PTNyNEe1
H1703	Mn;5SpVv[3Srb36gRZN{[Xl?	NFjnZ2gyOMLiwsXN	MkPINUBp	MlG3SG1UVw>?	Mmq3[IVkemWjc3XzJJRp\SCyZX3leJJmgGWmLXnu[JVk\WRiTWPINkBuWk6DIHHu[EBxem:2ZXnuJIxmfmWucx?=	NIPZWHozPDV\|MES3OS=>
H520	M3;sSmZ2dmO2aX;uJGF{e2G7	Moq5NVDDqML3TR?=	MnqzNVIhcA>?	MV;EUXNQ	MVHpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC\|dHHibYxqfHl?	NIrOTZkzPDV\|MES3OS=>
H1703	NV7YcGJ5TnWwY4Tpc44hSXO\|YYm=	NEjLUY0yOMLiwsXN	MXOxNkBp	NHHiV5hFVVOR	NIXxfGNqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	MlLwNlQ2OzB2N{W=
H520	NF6yeVhHfW6ldHnvckBCe3OjeR?=	Ml\MNVDDqML3TR?=	NWf3VW11PiCq	MV;EUXNQ	MYDzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy\|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV?	NInTUYIzPDV\|MES3OS=>
H1703	NYnSU4ExTnWwY4Tpc44hSXO\|YYm=	M3iydVExyqEEtV2=	NF7pdIg3KGh?	NYDwSmdZTE2VTx?=	M1fVVpNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBt\X[nbIOgc4YhfWKrcYXpeIlvNWOxbnr1[4F1\WRiTWPINkBqdiCyZX3leJJmgGWmLYTy[YF1\WUEoHPlcIwhdGmwZR?=	Ml32NlQ2OzB2N{W=
MC3T3-E1	MUDGeY5kfGmxbjDBd5NigQ>?	NES3UZoxNjNxMz:zNEDPxE1?	MkG1NUBp		Mm\5ZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC=	NWCweHhmOjR3MEK2PVY>
MC3T3-E1	NEXYN41HfW6ldHnvckBCe3OjeR?=	NF\iN4w{OCEQvF2=	MoO1NUBp		NVH1Wm5F[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	M17KNlI1PTB{Nkm2
HUVECs	MX3GeY5kfGmxbjDBd5NigQ>?	M2\yPFExyqEEtV2=	Mo\PNUBp		NEjScnZqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDDXGNNOSCycn;keYN1cW:w	M325O\|I1PDh5OU[0
AGS	NYXxbItUTnWwY4Tpc44hSXO\|YYm=	NHPVXIMyOMLiwsXN	Mn3NN\|DDqG2rbh?=		MV3pcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	Mk\5NlQ1Pzl4OEG=
MKN-45	MkjlSpVv[3Srb36gRZN{[Xl?	NXPXfop5OTEEoNM1US=>	MmOyN\|DDqG2rbh?=		NEnKO5ZqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB\|OB?=	M3HndFI1PDd7Nkix
AGS	NIXWOYVHfW6ldHnvckBCe3OjeR?=	M3PVcFExyqEEtV2=	NUjPS2NSOzEEoH3pci=>		NILteI1ifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	NFriNpMzPDR5OU[4NS=>
MKN-45	MWjGeY5kfGmxbjDBd5NigQ>?	NH7Jb\|EyOMLiwsXN	NF[5UFA{OMLibXnu		MXXheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=>	M3;pXVI1PDd7Nkix
AGS	NH70PVFHfW6ldHnvckBCe3OjeR?=	MkPqNVDDqML3TR?=	NEjLWFk{OMLibXnu		M1HudpNq\26rZnnjZY51dHliZHXjdoVie2W\|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w	MknFNlQ1Pzl4OEG=
MKN-45	MoLGSpVv[3Srb36gRZN{[Xl?	M3H3OVExyqEEtV2=	NY\oe3hrOzEEoH3pci=>		NF3WOGx{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	MVOyOFQ4QTZ6MR?=
DCs	MoDoSpVv[3Srb36gRZN{[Xl?	NV62RWFLOjEEoN88US=>	M1;q[\|HDqGh?		MVHk[YNz\WG\|ZYOgTWwuOTJicILv[JVkfGmxbh?=	Ml3KNlQ1OzR4M{[=
HUVEC	NHX3d4FHfW6ldHnvckBCe3OjeR?=	M4HH[VIxKM7:bdMg	NGPtXJc2KGh?	NY\SWZdXTE2VTx?=	MmnXdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO\|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?=	NH3yUIQzPDF6OUC2Ni=>
A 549	NVrrfYtoTnWwY4Tpc44hSXO\|YYm=	NH;yVYk2OCEQvF2=	NHrFe3EyKGh?		NHT4bVhl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>?	MUmyOFE4QTZ6OB?=
H520	Mlr3SpVv[3Srb36gRZN{[Xl?	NUW4Z2piPS9zMDFOwG0>	NInNPZIyKGh?	NXnwTHY1TE2VTx?=	NFjMTVNl\WO{ZXHz[ZMhVVOKMjDwdo91\WmwIHHzJJdmdGxiYYOgcXJPSSCuZY\lcJMhcW5iZ3XmbZRqdmmkLXX4dI9{\WRiY3XscC=>	M4nsW\|I1OTN6OUCz
H1703	M1PFS2Z2dmO2aX;uJGF{e2G7	NV;M[255PS9zMDFOwG0>	MnrZNUBp	NW[1UZFVTE2VTx?=	MljD[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	M1[2c\|I1OTN6OUCz
H520	NVrTNIpnTnWwY4Tpc44hSXO\|YYm=	NYPndZlEOTEEoNM1US=>	NWjQb4t1OTJiaB?=	NFzFRodFVVOR	MWLk[YNz\WG\|ZYOgUXNJOiCvUl7BJIFv\CCycn;0[YlvKHO2YXLpcIl1gSCrbjDn[YZqfGmwaXKteJJm[XSnZDDOV2NNSyClZXzsdy=>	MViyOFE{QDlyMx?=
H1703	MnL0SpVv[3Srb36gRZN{[Xl?	NHvrUWgyOMLiwsXN	M{XkbFEzKGh?	NH;UdXJFVVOR	M{nNXYRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	MoLnNlQyOzh7MEO=
MCF-7	M4DDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nSeVExyqEQvF2=	NGfwV4szPMLiaB?=		M{jFXolvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg>	NIDWVmozPDF{OEi1Ny=>
HPAEpiCs	NFHu[I1HfW6ldHnvckBCe3OjeR?=	NFv0U2YxNjFxMT:xNEDPxE1?	NYHBTmZTOSCq		NGToTWtqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjVGxCOsLicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:w	NFvW[HEzPDB4OUG1PC=>
podocytes	NXPzcHZ6TnWwY4Tpc44hSXO\|YYm=	NH;KXI8yOMLizszN	M3HK[VEhcA>?		NUDXOZFKcW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?=	M3fReVI1ODN4MkGy
MCF-7	NV[wO3lTTnWwY4Tpc44hSXO\|YYm=	MWSxNOKh\|ryP	M3jwVlEhcA>?	Mn7PSG1UVw>?	M{P1ZZJm\HWlZYOgeIhmKFeDLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQheDN6IF3BVGs>	MUmyOFAyQTB7MB?=
MCF-7	NWLaU2VuTnWwY4Tpc44hSXO\|YYm=	MV:xNOKh\|ryP	NVfBOoszOjRiaB?=	MmLwSG1UVw>?	NUPx[41pcW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	M{XzN\|I1ODF7MEmw
HAPI	NF\tbWNHfW6ldHnvckBCe3OjeR?=	MnXUNVAwOjBxNEFCpO69VQ>?	NVTyfmJFOSCq		MnWybY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB\|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25?	MkLtNlM6PjlzMkC=
HAPI	M4jMRWZ2dmO2aX;uJGF{e2G7	MX6yNOKh\|ryPwrC=	NWjEb3BpOSCq	MmXkSG1UVw>?	M1jLfIF1fGWwdXH0[ZMhXEOGRD3pcoR2[2WmIHHjeIl3[XSrb36gc4YhcU6RUzDhcoQheHKxZIXjeIlwdg>?	NHTXVFIzOzl4OUGyNC=>
HepG2	M2HwUmZ2dmO2aX;uJGF{e2G7	NHHjbG8{PTBibl2=	MXiyOEBp		M{nQSYlvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?=	NIPDU40zOzl\|M{G5PC=>
AGS	NWjCW5VuTnWwY4Tpc44hSXO\|YYm=	M3;wPFExyqEQvF2=	MUSzNEBucW5?		MknVbY5pcWKrdIOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN	NVzze41kOjN6NUC5PVQ>
HepG2	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Ps[FAuPTBizszN	NEPEcm81QCCq		NFTjO\|hqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NHnXUG4zOzhyN{WwPC=>
BEL7404	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOwMVUxKM7:TR?=	Ml70OFghcA>?		MYrpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NIrzRo0zOzhyN{WwPC=>
HL7702	M1Gzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzFW45ZOC13MDFOwG0>	NH7aRoE1QCCq		M2D5c4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MUCyN\|gxPzVyOB?=
HepG2	NV7NWHBkTnWwY4Tpc44hSXO\|YYm=	MXuwMVUxKM7:TR?=	MWqyOEBp		NGH6d2ZqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIICzPEBld3ewc4Ty[YFuKHC{b4TlbY5{KE2DUFvBVGszNCCDVF[yMEBOW0tzIHHu[EBJW1B{NzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MorFNlM5ODd3MEi=
BEAS-2B	NFjlU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	NWO0Z5pQOzBibXnu		M4XaZpJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=>	NUPEPZRxOjN5OESwN\|Q>
BEAS-2B	NXn5Ro5MS3m2b4TvfIl1gSCDc4PhfS=>	M2f1clExKM7:TR?=	MkP2N\|AhdWmw		NFHlNHNqdmirYnn0[YQhfGinIHnuZ5Jm[XOnIHnuJGxFUCCjbnSgTWwuQCCneIDy[ZN{cW:w	M{LwN\|I{Pzh2MEO0
BEAS-2B	MkDISpVv[3Srb36gRZN{[Xl?	NX\BenZtOTBizszN	MXqzNEBucW5?		Momy[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY3HzdIF{\S1\|LDDCZYQh[W6mIH\hdy=>	NWXod5RlOjN5OESwN\|Q>
H9c2	MVzGeY5kfGmxbjDBd5NigQ>?	M2DEW\|AvODFxMD6xM\|Eh\|ryP	MkjUNUBp		MmqyZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wLDDtVm5CKGyndnXsd{wh[W6mIIDyc41wfGW{IHHjeIl3cXS7	M1HQZVI{Pzd2MkWy
H9c2	NIfXSJNHfW6ldHnvckBCe3OjeR?=	M2PZbVEh\|ryP	NGriem0yKGh?		NIT1eWtz\WS3Y3XzJHRPTi4QsTDkbZJm[3SueTDzeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	NHfEZ5czOzd5NEK1Ni=>
U937	NYW2bWZ3TnWwY4Tpc44hSXO\|YYm=	NIDr[FkyOMLizszNxsA>	M3\nblEhcA>?		MX;hZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	MnjzNlM4ODd\|OEe=
U937	M33PemZ2dmO2aX;uJGF{e2G7	MkPrNVDDqM7:TdMg	MlHXNUBp		NHi5Zoli[nKxZ3H0[ZMh[2GoZnXpcoUucW6mdXPl[EBOU1BvMTDkc5dvNXKnZ4XsZZRqd25iYX7kJHBROkGlzsGgeZAuemWpdXzheIlwdg>?	NFTwSZIzOzdyN{O4Oy=>
U937	MWTGeY5kfGmxbjDBd5NigQ>?	M1jQblExyqEQvF5CpC=>	NXzxeod2OSCq		M1vKW5N2eHC{ZYPz[ZMh[y2MdX6gZY5lKEOURVKgdIhwe3Cqb4L5cIF1cW:wIHnuJINi\m[naX7lMZRz\WG2ZXSgZ4VtdHQEoB?=	MnT5NlM4ODd\|OEe=
A549	MWPGeY5kfGmxbjDBd5NigQ>?	M{LUUlAvOy9\|L{OwJO69VQ>?	NXnkOVNDOSCq		MVLzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?=	NX\oU2E6OjN4OEC2O\|Q>
A549	NWHWRZlDTnWwY4Tpc44hSXO\|YYm=	MnHJNVDDqM7:TdMg	NEfXbYcxNTNyIH3pci=>		NV32PFlpcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	M2raSlI{PjhyNke0
A549	NXLXWmF5TnWwY4Tpc44hSXO\|YYm=	NFPKUIcyOMLizszNxsA>	NVS0PWhsOSCq		Mmi5bY5pcWKrdIOgRXRR\|rOVIHnu[JVk\WRiTl[t{tpDKHB4NTDzeYJ2dmm2IIDoc5NxcG:{eXzheIlwdiCjbnSgUmYu\|rqEIIDyc41wfGW{IHHjeIl3cXS7	NGXtdZczOzZ6ME[3OC=>
A549	NXvCcYhVTnWwY4Tpc44hSXO\|YYm=	NGfNcFMyOMLizszNxsA>	NFLoXmkyKGh?		NYjNUXBPemWmdXPld{BCXFEQs2Otd5RqdXWuYYTl[EBkWEyDMjDwbI9{eGixconsZZRqd28EoB?=	NXnadlJoOjN4OEC2O\|Q>
A549	NHjZSodHfW6ldHnvckBCe3OjeR?=	MkCzNVDDqM7:TdMg	MXuxJIg>		M372SZJm\HWlZYOgRXRR\|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg	MmjaNlM3QDB4N{S=
PC12	MX;GeY5kfGmxbjDBd5NigQ>?	MV[xNE8zOC92MDFOwG0>	NEDnTWsyyqCq		MX\pcohq[mm2czDKUmsh[W6mIICzPC=>	M37EZVI{PTh2M{W3
HK-2	MmjCRZBweHSxc3nzJGF{e2G7	MWiyNOKh\|ryP	MnfXNlQhcA>?		MVXpcohq[mm2czDFVmsh[W6mIICzPG1CWEt?	MX2yN\|U1OzF3MR?=
H9c2	MXjGeY5kfGmxbjDBd5NigQ>?	M1\HN\|HDqM7:TR?=	NFT4S3gyKGh?		NV3HZnVxemWmdXPld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCvUl7BJIxmfmWuczDhcoQheHKxbX;0[ZIh[WO2aY\peJk>	M1vSWlI{OzV\|Nkm5
H9c2	NITsVZhHfW6ldHnvckBCe3OjeR?=	M37nfFHDqM7:TR?=	NIeyPZgyKGh?		M2f4[5Jm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk>	NHryT5MzOzN3M{[5PS=>
H1650	NYDSfJhlTnWwY4Tpc44hSXO\|YYm=	MkHFNVDDqM7:TdMg	M4X6[VEhcA>?	M4\6d2ROW09?	NEfhW4pl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	M4D2WFI{OjJ6Nkm2
H1703	MmHMSpVv[3Srb36gRZN{[Xl?	NH[1N\|IyOMLizszNxsA>	M2DpVlEhcA>?	MYDEUXNQ	MkHS[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	M3r4d\|I{OjJ6Nkm2
H1650	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPIelM1OTEEoN88UeKh	NFL5[\|AyKGh?	MlzXSG1UVw>?	M{fWXYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl?	NX3Ib2xWOjN{Mki2PVY>
H1703	NXq3TItvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELJZWgyOMLizszNxsA>	NYr1eYFKOSCq	MYDEUXNQ	Mnm0[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	M2HFTlI{OjJ6Nkm2

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Water	Insoluble
	Ethanol	'12 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	OC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=NC=C3)C4=CC=C(F)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)